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Abstract
Background—Little is known about fish intake throughout the life course and the risk of breast 
cancer.
Methods—We used data on the first residence of 9,340 women born 1908–1935 in the Reykjavik 
Study as well as food frequency data for different periods of life from a subgroup of the cohort 
entering the AGES-Reykjavik Study (n = 2,882).
Results—During a mean follow-up of 27.3 years, 744 women were diagnosed with breast cancer 
in the Reykjavik Study. An inverse association of breast cancer was observed among women who 
lived through the puberty period in coastal villages, compared with women residing in the capital 
area (HR = 0.78, 95% CI: 0.61, 0.99). In the subgroup analysis of this Icelandic population, 
generally characterized by high fish intake, we found an indication of lower risk of breast cancer 
among women with high fish consumption (more than 4 portions per week) in adolescence (HR 
0.71, 95% CI, 0.44, 1.13) and midlife (HR 0.46, 95% CI, 0.22, 0.97), compared with low 
consumers (2 portions per week or less). No association was found for fish liver oil consumption 
in any time period which could be due to lack of a reference group with low omega-3 fatty acids 
intake in the study group.
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Conclusion—Our findings suggest that very high fish consumption in early to midlife may be 
associated with a reduced risk of breast cancer.
Impact—Very high fish consumption in early adulthood to midlife may be associated with 
decreased risk of breast cancer.
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Introduction
Increasing evidence suggests that dietary factors play an important role in both the 
prevention and development of breast cancer (1), although no clear relation has been 
established (2). A meta-analysis from 2013 examined the association between breast cancer 
and intake of fish as well as n-3 polyunsaturated fatty acids (n-3 PUFA) (3). A risk reduction 
for breast cancer was observed for high intake of marine derived omega-3 PUFA, mainly 
consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). No association 
was found for total fish consumption, where information on different species (lean and fatty 
fish) was lacking (3) Recent studies have also reported non-significant association between 
total fish intake and breast cancer (4–6). The associations between hormone receptor status 
of breast tumors and fish consumption are unclear (7).
A possible explanation for inconsistent results could be the timing of the exposure 
measurement. Cancers can have a long latency period from initiation to cancer detection, 
making different exposure periods of potential importance, rather than just around the time 
of detection (8). Dietary habits in early life, especially around puberty when the mammary 
tissue is growing and maturing (9–11), may therefore be of significance for breast cancer 
risk.
Few studies have specifically explored the potential link between fish consumption in 
adolescence and breast cancer risk and none of these studies has reported significant 
associations (12–15). Some (16, 17), but not all studies (15), on vitamin D, an important 
component in certain types of fish, have reported an inverse association with breast cancer in 
the adolescent period. However, studying dietary exposure in early-life is challenging due to 
the need for follow-up for many decades or alternatively, relying on dietary data from distant 
recall which are often susceptible to bias (18).
According to an Icelandic dietary survey from 1939–1940, dietary patterns differed greatly 
between rural and coastal areas in the early and mid-20th century. In this population, 
characterized by high fish intake, fish consumption was substantially higher in coastal 
villages than in other parts of the country. For example, average fish consumption was 140 
grams per day (g/d) in rural areas, 213 g/d in the capital area and 354 g/d in coastal villages 
(19). Parallel to our earlier studies on prostate cancer (20–22), this variation provides us with 
a unique opportunity to prospectively explore the impact of high fish consumption in 
adolescence on the risk of breast cancer. By using the population-based data of the 
Reykjavik Study, we investigated whether residence (as a proxy for diet) in adolescence was 
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associated with the risk of breast cancer. Furthermore, using validated food frequency data 
from a subgroup of the Reykjavik Study participating in the Age, Gene/Environment 
Susceptibility (AGES) Study, our aim was to explore whether diet in both adolescence and 
midlife was associated with breast cancer risk.
Materials and Methods
Residence analysis—Reykjavik Study
Population—The Reykjavik Study is a population-based prospective cohort. The Icelandic 
Heart Association initiated the study in 1967. All women born between 1908 and 1935 and 
living in the capital area in December 1966 were invited to participate (23). 10,049 women 
entered the study (71% response rate), in six stages from 1967 until 1996 (24). We excluded 
women who were diagnosed with breast cancer prior to entry and for who follow-up was 
incomplete (n = 145).
Exposure assessment—Classification of residence—Participants provided 
information on residence at birth and throughout their lives. Classification of early residence 
has been described in our earlier studies (20). In short, every community (n = 245) in Iceland 
was classified into 4 categories: capital area, coastal villages, rural areas, and combinations 
of coastal villages and rural areas (20). We excluded participants without available 
information on residence (n= 238) and those whose first residence was a combination of 
coastal village and rural area (n=341), since it would be hard to draw any dietary based 
conclusions for this particular group. This left 9340 women in the residence analysis.
Covariate assessment—Reykjavik Study—From the Reykjavik Study we retrieved 
baseline information on age at entry (continuous), height (continuous), year of birth (1908–
1914, 1915–1919, 1920–1924, 1925–1929, 1930–1935), education (primary, secondary, 
college/university), body mass index (BMI)(continuous), parity (no children, 1–2, 3 and 
more), and physical activity (no, yes) (see table 1).
Covariate assessment—Cancer Detection Clinic Cohort—Since data on 
reproductive history were generally not collected in the Reykjavik Study, information on 
potential reproductive confounders for breast cancer was obtained from the Cancer 
Detection Clinic Cohort (CDC cohort), established 1964. This cohort includes data collected 
as part of nationwide, centralized cervical- and breast cancer screening programs. All 
Icelandic women aged 20 – 69 years are invited to visit the CDC every other year for 
screening cancer of the cervix (from the age of 20) and breast (from 40 years of age) (25). 
When data from the two cohorts were linked, about 91% of women in the Reykjavik Study 
had attended the Cancer Detection Clinic at least once. For this study, information closest to 
the study´s endpoint (breast cancer diagnosis, death, or end of the year 2013) was retrieved 
and linked with our data. From the CDC cohort we primarily retrieved information on age at 
menarche (continuous) and age at first birth (none, 24 and younger, 25 and older). The 
variable "age at menarche" had 933 missing values. The variable "age at first birth" had 924 
missing values, which we were able to reduce to 683 by adding information on parity from 
the Reykjavik Study. We placed the 241 women who had missing values in "age at first 
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birth" from the CDC cohort, and had no children at entry to the Reykjavik Study in the "no 
birth" category. We categorized the 113 women who were classified as childless in the CDC 
cohort but had a child according to the Reykjavik Study, into the "25 and older" category, 
since women were at least 33 years of age upon entry into the Reykjavik Study.
We also evaluated information on the total months of breastfeeding (never, 1–6 months, 7 
months and more), the use of hormonal replacement therapy (HRT) (never, ever) and use of 
oral contraceptives (never, ever).
Follow-up and outcome—Participants were followed from their entry into the study 
(between 1967 and 1996) until their diagnosis of breast cancer, death, or the end of the 
observation period (December 31st, 2013). We ascertained breast cancer diagnoses through 
the nationwide Icelandic Cancer Registry (26). Information on the cause of death was 
obtained from the Directorate of Health. Due to Iceland’s computerized national roster and 
each person’s unique personal identification numbers, follow-up was virtually complete 
(27). Information on the receptor status of the tumors was only used in the analysis of 
residence. We had information on receptor status in 76% of cases for estrogen (ER) positive 
or negative tumors and 74% of cases for progesterone (PR) positive or negative tumors. 
Receptor status was further categorized as ER/PR positive, ER/PR negative, ER positive PR 
negative (28).
Statistical analyses—We used Cox proportional hazard regression models to calculate 
HRs and 95% confidence intervals (95 % CI) for the diagnosis of breast cancer by residence 
(coastal village or rural area) in early life, from the time of entry into the Reykjavik Study. 
Residence in the capital area was the reference category. In line with WHO´s definition of 
the adolescence period (29), we also stratified our data into three categories, based on 
women’s age when they moved away from their first residence in rural areas and coastal 
villages: 1) age 11 and younger, 2) between the ages of 12 and 19, and 3) at age 20 and 
older. Residence in the capital area was also the reference. The first multivariable model was 
adjusted for age (continuous) at entry into the Reykjavik Study. The second model (HRa) 
was additionally adjusted for birth cohort, education, parity, physical activity, BMI and 
height, categorized as described in table 1. The third model (HRb) was additionally adjusted 
for age at menarche and age at first birth, obtained from the CDC cohort.
Since age both at menarche and at first birth are strong risk factors for breast cancer (2), a 
sensitivity analysis was conducted in order to compensate for the missing values for these 
variables. Multiple imputation was used to predict missing values for "age at menarche" 
(10% missing) by mean matching after stratifying the variables: age at entry, birth cohort 
and education. Missing values for “age at first birth” were included in the analyses as a 
special category (7% missing). Other variables from the CDC cohort were not included due 
to even higher number of missing values.
In addition, we calculated HR and 95% CI for tumor receptor status according to residence 
in early life. As above, the first model was adjusted for age only, while the second model 
(HRa) was additionally adjusted for birth cohort, education, parity, regular exercise, BMI 
and height (data shown in supplemental table 1).
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Dietary analysis—The AGES-Reykjavik Study
Exposure measurement—ascertainment of dietary habits—The AGES-Reykjavik 
Study, a sub-cohort from the Reykjavik Study, was initiated in 2002. Of the women 
participating in the Reykjavik Study, 3,326 were randomly enrolled between 2002 and 2006, 
as described by Harris et al (23). Participants entering the AGES-Reykjavik Study provided 
retrospective information on dietary habits in early life (ages 14–19), in midlife (ages 40–
50), as well as current diet in late life (ages 66–96). Participants received careful instructions 
at the clinic on the filling out of a validated food frequency questionnaire (AGES-FFQ) (30, 
31) (Figure 1). There were three questions on fish consumption in the FFQ. The first one 
concerned the frequency of fish meals per week (p/w) (salted or smoked fish included). The 
second question concerned the weekly frequency of using fish as a topping on bread and in 
salad, and the third one was on the frequency of salted or smoked fish intake p/w. Total fish 
intake was based on the first two questions. Possible response categories were; 1) never, 2) 
less than once a week, 3) 1–2 times a week, 4) 3–4 times a week, 5) 5–6 times a week, 6) 
daily, and 7) more than once a day. Due to the different amounts of fish consumed as a meal 
or topping on bread, we used information on average portion size from the Icelandic national 
nutrition surveys (32, 33) to estimate total fish consumption p/w. One portion of fish was 
estimated to be 150g for fish as a main meal and 40g for fish as a bread topping. Numerical 
values for portions of fish were calculated accordingly (22). Total fish consumption was 
divided into three groups, i.e., high (> 4 portions p/w), moderate (>2–4 portions p/w) or low 
(≤ 2 portions p/w). The FFQ did not contain questions on the type of fish. However, cod and 
haddock were the fish most commonly consumed in the early 20th century as well as today 
(32, 33).
Fish liver oil intake (liquid or capsules) is a cultural tradition in Iceland (33). It was also 
assessed for each period of life, using one question with the same response alternatives as 
were used for fish meals, omitting the last option of more than once a day.
The FFQ designed for the AGES-Reykjavik Study has been validated for both midlife and 
current dietary habits later in life (30, 31). In short, the correlation between the reference 
method and the AGES-FFQ for midlife was r = 0.58, p = 0.001 for fish oil consumption. The 
question on midlife fish consumption showed a lower correlation but was still within the 
acceptable range (r = 0.281, p = 0.004) (31). Because of the low validity for overall current 
fish intake in late life, these data were not used to study breast cancer risk (30).
Covariate assessment—From the AGES-Reykjavik Study we retrieved information, 
gathered at entry, on age (continuous), year of birth (1908–1919, 1920–1924, 1925–1929, 
1930–1935), education (primary, secondary, college/university), age at first birth (none, age 
24 and younger, 25 and older), family history of breast cancer (mother, sister and/or 
daughter ever diagnosed with breast cancer), use of hormonal replacement therapy (never, 
ever), use of oral contraceptive (never, ever), use of alcohol in midlife (never, ever), BMI in 
late life (continuous), alcohol consumption in late life (0, 1–10g/week, >10g/week) and 
physical activity in midlife and late life (never/rarely, occasionally, moderately/often). From 
the Reykjavik Study we retrieved values on BMI in midlife (continuous) and height in 
midlife (continuous).
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Information on dietary covariates was retrieved from the AGES-FFQ. For all periods, 
selected covariates on consumption were milk, salted or smoked fish, rye bread, meat, total 
fish and fish liver oil. The cut off points can be seen in table 2. We also included information 
on first residence, categorized into four places as described in residence analysis.
Statistical analyses and follow-up – dietary analysis—We used Cox proportional 
hazard regression models to calculate HR and 95 % CI for incident breast cancer, from entry 
to the AGES-Reykjavik Study, according to total fish consumption in adolescence and 
midlife, using the lowest category as a referent. The same method was used for the fish liver 
oil analyses, adding late life consumption.
For both exposures, in all time periods, the first model was adjusted for age (as a continuous 
variable) at entry. For the adolescent period, information on education, family history of 
breast cancer, BMI in midlife, age at menarche and age at first child was added to the second 
model (HRa). In the third model (HRb), information on dietary factors: rye, milk, meat, 
salted or smoked fish, fish (for the fish liver oil analysis) and fish liver oil (for the fish 
analysis) were added. The same models, as described for adolescence, were used for both 
midlife and late life periods, except information on alcohol consumption was added as a 
covariate in the second model (HRa) as well as current values for BMI and dietary factors. 
Further adjustment for physical activity, use of oral contraceptives or HRT did not 
significantly change our results and were therefore not included in the models.
Participants were followed from their entry into the study until a diagnosis of breast cancer, 
death or the end of the observation period (December 31st, 2013). We ascertained breast 
cancer diagnosis and the cause of death the same way as described for the residence analysis 
(26).
For all statistical analysis we used SPSS software, version 22.0 (SPSS Inc., Chicago, 
Illinois; www.spss.com) and R Core Team (2014). R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria; (http://
www.R-project.org/) The study protocol was approved by the Icelandic Ethical Review 
Board and the Icelandic Data Protection Authority (VSN b2007120014/03-7).
Results
Residence analysis
We included 9,340 women in our analysis of early life residency (Figure 1). The mean age at 
entry into the Reykjavik Study was 53.9 years (SD = 9.9). All participants lived in the 
capital area at study entry, but only 37% were born and raised in the capital area; 35% were 
born and raised in a coastal village, and 28% were born and raised in a rural area. During an 
average follow-up of 27.3 years, 744 (8%) were diagnosed with breast cancer. The mean age 
at diagnosis was 69.7 years (SD = 11) and sixty-five women (9%) were diagnosed before the 
age of 55.
Table 1 presents the baseline characteristics of the study population by first residence. The 
average duration of first residence was longest in the capital area because most of the 
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women born there never moved away. A higher proportion of women raised in the capital 
area had college/university degrees, were taller and exercised more frequently than women 
raised in other areas. Women with first residence in rural areas had fewer children on 
average and were older when having their first child. Women raised in coastal villages were 
on average older at menarche and also reported the highest frequency of fish consumption in 
adolescence in the AGES-Reykjavik Study.
Compared to women born and raised in the capital area, early life residence in coastal 
villages and rural areas were both weakly associated with a lower risk of breast cancer 
diagnosis, HR = 0.87, 95 % CI: 0.72, 1.04, and HR = 0.88, 0.73–1.07, respectively. When 
looking at the duration of residence from birth outside the capital area, we observed a 
significant inverse association for breast cancer diagnosis only among women who lived 
beyond the puberty period (at least to age 20 years or longer) in coastal villages, compared 
to women residing in the capital area (HR = 0.78, 95% CI: 0.61, 0.99). No statistically 
significant associations were observed between any length of residence and breast cancer in 
the rural areas (Table 2).
In the final model (HRb) we included adjustment variables (age at menarche and age at first 
child) obtained from the CDC cohort. When we conducted sensitivity analysis, using 
imputed missing indicators for these variables, the pooled risk estimate for women who lived 
beyond the puberty period in coastal villages attenuated slightly (HR = 0.83, 95% CI: 0.66, 
1.04).
When data were analyzed by hormone receptor status, we found a borderline significant 
association between women with first residence in coastal village and ER/PR negative status 
and ER positive/PR negative status, adjusted for major risk factors (HR = 0.64, 95% CI 0.41, 
1.01 and 0.60, 0.35, 1.03, respectively). (Supplementary table 1).
Dietary analyses
The dietary analyses were based on participants providing information on fish and fish oil 
intake at different time periods at their time of entry into the Reykjavik-AGES cohort. 
During the follow-up through 2013 (mean 8.2 years), 91 women were diagnosed with breast 
cancer. Their mean age at entry was 77.0 years (SD = 6.0) and their mean age at diagnosis 
was 81.2 years (SD = 6.5).
Table 3 shows the characteristics of the subpopulation providing information on fish 
consumption in early - (n = 2,882) and midlife (n = 2,879). Women with high fish 
consumption in early life were younger at first childbirth and also had the highest 
consumption of meat, fish liver oil and salted fish, compared to women with lower fish 
consumption. Women with high intake of fish in midlife were more physically active, 
consumed less meat, less salted fish, less rye bread and less alcohol, drank more milk and 
used less oral contraceptives, compared to women with lower fish intake in midlife.
Table 4 presents hazard ratios, with 95% CI for breast cancer by total fish and fish liver oil 
intake. Compared to women consuming two portions or less per week in adolescence, 
women with high consumption (> 4 portions p/w), showed lower risk of breast cancer, albeit 
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not statistically significant (HR 0.71, 0.44, 1.13). For the midlife period, we found 
statistically significant risk reduction among women with high fish consumption (HR 0.46, 
95% CI 0.22–0.97) compared to lower fish consumption. When information on early life 
residence was added to the models, our estimates did not change considerably. No 
significant association was found between fish liver oil consumption and breast cancer risk 
in any time period.
Discussion
In this population-based prospective cohort study, we did not observe a strong association 
between residence and breast cancer. However, prolonged stay in a coastal village for the 
first 20 years of life or longer was associated with a lower risk of breast cancer, compared to 
residence in the capital area. In the subgroup analysis on dietary habits, high fish 
consumption during midlife was associated with a lower risk of breast cancer while 
suggestive association was observed for consumption in adolescence.
Risk reduction for breast cancer has previously been linked with vitamin D (17, 34, 35) and 
marine derived n-3 PUFA (3, 34)frequently found in fatty fish and fish liver oil. However, to 
our best knowledge, no study has found an association between adolescent total fish 
consumption and breast cancer risk(12–15), and studies on adult total fish consumption have 
not found strong beneficial association either (5, 6, 36–38). Haddock and cod, the most 
common fish types consumed in Iceland are lean species containing only modest amounts of 
vitamin D or about 0.9 µg/100g and 0.3g of n-3 PUFA/100 g (39). Nevertheless, we cannot 
exclude their contribution due to the uniquely high amounts of fish consumed in our cohorts, 
when compared with previous studies. The observed discrepancy with our analysis on fish 
liver oil, a common supplement in Iceland, rich in vitamin D and n-3 PUFA, might be due to 
the unusually high amount of retinol (30,000µg/100g) found in Icelandic fish liver oil for 
most of the 20th century. Retinol can interfere with the absorption, transportation and 
conversion to vitamin D’s active form (40, 41).Consequently, the high consumption of fish 
rather than fish liver oil may have promoted better absorption and utilization of vitamin D. 
Icelandic fish liver oil also contains n-3 PUFA. However, the Icelandic population has high 
levels of EPA and DHA in both diet and plasma (42). It might therefore be possible that the 
study population has already reached a beneficial threshold level of marine derived n-3 
PUFA for breast cancer risk.
However, the observed risk reduction for women residing beyond puberty in coastal villages 
could also be due to lower total energy intake in adolescence, previously linked with risk 
reduction for breast cancer(43, 44). The total energy intake of people residing in coastal 
villages in the first half of the 20th century was lower than in other areas (19). Additionally, 
as seen in table 1, we observed a statistically significant regional difference showing lower 
adult height and higher age at menarche on average among women born and raised in coastal 
villages, which are both important factors in evaluating childhood nutritional status and the 
possible risk of future breast cancer (45). During the period between menarche and first-term 
pregnancy, the breast tissue in women undergoes increased cellular proliferation, and breast 
cancer risk accumulates rapidly up to the terminal differentiation accompanying the first full 
Haraldsdottir et al. Page 8
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
term pregnancy (10). This period of early adulthood is therefore possibly of great 
importance for environmental exposure such as diet.
Also, risk factors have been shown to vary in their relevance to breast tumors depending on 
hormonal receptors status (28). Analogous to the findings on diet in previous studies (46, 
47), we observed borderline inverse association between early life residence in coastal 
villages and ER/PR negative tumors. This suggest a stronger environmental influence for ER 
negative tumors, where hormonal factors might be less dominating (47). Our finding for ER 
positive and PR negative tumors might also indicate the importance of PR status of tumors.
Major strengths of our study are the distinct residency-based variations in early life fish 
consumption, the ability to study dietary factors across the life span as well as the 
established population-based cohorts with extensive covariate information. Additionally, the 
record linkage to the nationwide Cancer Registry of Iceland provided detailed and valid 
assessment of the outcome. A major limitation of our study is that information on the 
frequency of fish consumed during midlife and adolescence is retrospective in nature. As a 
result, there may be a non-differential measurement error, and there is always uncertainty in 
assessing dietary habits stretching over a 40-to-50-year period (48). Yet, food-related 
memory from childhood to four decades later can be as accurate as food-related memory of 
current diet, especially for food items eaten rarely or daily (49), possibly explaining no dose 
response found for fish consumption in adolesecnece since few women reported 
consumption from 2 up to 4 portions per week (30). Also, we do not have information on 
cooking methods in our study. However, information from a national nutrition survey 
conducted in 1990 showed that 64% of total fish consumed as a main meal was boiled or 
baked (32). Another limitation of our study is the lack of information about total energy 
intake and growth in early life. We were only able to adjust for body mass index measured in 
midlife, which may only indirectly indicate total energy intake (50). Also, the classification 
of residence into rural areas and coastal villages is based on geographical and historical 
evidence that does not consider variability of remoteness or isolation. Finally, we do not 
have complete information on reproductive factors like the use of HRT and oral 
contraceptives and breastfeeding for all women in the residence analysis, and we cannot 
exclude unmeasured confounders in our study..
Our data imply that very high fish consumption in early to midlife may be associated with a 
decreased risk of breast cancer. However, we need larger prospective studies to further 
clarify the effects of very high fish consumption on breast cancer risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Selection of participants from the Reykjavik Study and the Age, Gene/Environment 
Susceptibility (AGES)-Reykjavik Study, Iceland, 1967 – 2013.
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